Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$49K Sell
2,679
-399
-13% -$7.97K ﹤0.01% 6853
2014
Q2
$66K Buy
3,078
+454
+17% +$9.72K ﹤0.01% 6492
2014
Q1
$60K Sell
2,624
-1,448
-36% -$35.4K ﹤0.01% 6603
2013
Q4
$99K Buy
4,072
+2,350
+136% +$55.4K ﹤0.01% 6084
2013
Q3
$41K Buy
1,722
+492
+40% +$10.5K ﹤0.01% 7115
2013
Q2
$25K Buy
+1,230
New +$30.8K ﹤0.01% 7615

Other funds holding SRDX

UBS's SRDX Position: Q3 2014 in Review

UBS reduced its Surmodics (SRDX) stake by 13% in Q3 2014, selling an estimated $7.97K and leaving 2,679 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #6853.

UBS first reported a position in SRDX in Q2 2013 and has held it in 6 quarters since. The position peaked at $99K in Q4 2013. 112 funds tracked by Wall St. Rank hold SRDX as of Q3 2014.

  • UBS held 2,679 shares of Surmodics worth $49K as of Q3 2014.
  • UBS sold 399 Surmodics shares in Q3 2014, an estimated $7.97K.
  • Surmodics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6853 holding.
  • UBS first reported a position in Surmodics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Surmodics position peaked at $99K in Q4 2013.
  • 112 funds tracked by Wall St. Rank held Surmodics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.